Clinical Trials Browser

ulixertinib × Dermatologic × Clear all

Uveal Melanoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

45 enrolled

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

Clinical Trials

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors